<DOC>
	<DOCNO>NCT00002933</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irinotecan treating patient metastatic recurrent colorectal cancer .</brief_summary>
	<brief_title>Irinotecan Treating Patients With Metastatic Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Confirm great 20 % response rate irinotecan patient metastatic recurrent colorectal cancer receive prior chemotherapy advance disease . II . Characterize pharmacokinetic parameter irinotecan metabolite SN-38 relationship response toxic effect . III . Characterize tumor sample topoisomerase I activity , proliferative fraction ( ki67 expression ) , p53 expression determine whether clinical response related tumor characteristic patient population . IV . Determine vitro inhibition topoisomerase I activity irinotecan , SN-38 , camptothecin analog evaluate whether degree vitro sensitivity irinotecan and/or SN-38 associate clinical response patient . VII . Determine frequency somatic mutation follow irinotecan correlate pharmacologic parameter . OUTLINE : Patients receive irinotecan IV start dose weekly 4 week follow 2 week rest . Treatment continue absence disease progression unacceptable toxicity . Tumor status reassess every 12 week study . Patients attain complete response may receive additional course treatment . Patients follow death . PROJECTED ACCRUAL : A total 54 patient accrue study rate 25 patient per year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic recurrent adenocarcinoma colon rectum incurable surgery radiation therapy A metastatic lesion liver lung evaluate definitive surgical treatment consider study Measurable disease require Elevated CEA , hepatomegaly ascites , pleural effusion , positive nuclear scan bone scan , poorly define pelvic abdominal mass NOT consider measurable disease Must measurable disease outside radiation port progression disease within previously radiate area Must eligible biopsy malignant lesion No ascites detectable physical exam No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Greater 12 week Hematopoietic : WBC least 4,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.2 mg/dL SGOT le 4 time upper limit normal Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Other : No history malignancy except curatively treat nonmelanoma skin cancer carcinoma situ cervix No active infection serious medical condition deem unacceptable Negative pregnancy test Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy advance disease Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy Surgery : At least 3 week since surgical procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>